Henry Schein (NASDAQ:HSIC) Price Target Raised to $95.00

Henry Schein (NASDAQ:HSIC) had its price target lifted by UBS Group from $94.00 to $95.00 in a report issued on Wednesday,Benzinga reports. They currently have a neutral rating on the stock.

Several other brokerages have also recently weighed in on HSIC. Piper Sandler upped their price target on Henry Schein from $91.00 to $95.00 and gave the stock an “overweight” rating in a research note on Wednesday, July 29th. Citigroup reissued a “buy” rating and set a $112.00 price objective (up from $100.00) on shares of Henry Schein in a research report on Wednesday, August 5th. Wall Street Zen upgraded shares of Henry Schein from a “hold” rating to a “buy” rating in a report on Monday, August 17th. BTIG Research boosted their target price on shares of Henry Schein from $100.00 to $110.00 and gave the company a “buy” rating in a report on Wednesday, August 19th. Finally, BMO Capital Markets initiated coverage on shares of Henry Schein in a research report on Wednesday, July 8th. They issued a “market perform” rating and a $85.00 target price on the stock. Eight research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Henry Schein has an average rating of “Moderate Buy” and a consensus target price of $93.57.

Henry Schein Stock Up 0.9%

HSIC traded up $0.74 on Wednesday, hitting $86.05. The company had a trading volume of 1,375,024 shares, compared to its average volume of 1,267,797. The stock has a fifty day simple moving average of $86.14 and a 200-day simple moving average of $81.30. The company has a debt-to-equity ratio of 0.60, a current ratio of 1.32 and a quick ratio of 0.73. The firm has a market capitalization of $9.59 billion, a P/E ratio of 23.58, a P/E/G ratio of 1.56 and a beta of 0.87. Henry Schein has a 52-week low of $68.70 and a 52-week high of $92.18.

Henry Schein (NASDAQ:HSIC) last posted its earnings results on Tuesday, November 3rd. The company reported $1.56 earnings per share for the quarter, topping analysts’ consensus estimates of $1.36 by $0.20. Henry Schein had a return on equity of 15.97% and a net margin of 2.96%. The firm had revenue of $3.47 billion for the quarter, compared to the consensus estimate of $3.48 billion. During the same quarter in the prior year, the business earned $1.38 EPS. The business’s revenue for the quarter was up 4.0% on a year-over-year basis. As a group, equities analysts expect that Henry Schein will post 5.55 EPS for the current fiscal year.

Institutional Investors Weigh In On Henry Schein

Institutional investors and hedge funds have recently made changes to their positions in the company. Operose Advisors LLC purchased a new stake in shares of Henry Schein during the second quarter valued at $33,000. Trust Co. of Vermont bought a new position in Henry Schein during the 2nd quarter valued at about $42,000. Root Financial Partners LLC bought a new position in Henry Schein during the 3rd quarter valued at about $50,000. Versant Capital Management Inc lifted its stake in Henry Schein by 175.4% during the 2nd quarter. Versant Capital Management Inc now owns 617 shares of the company’s stock valued at $52,000 after acquiring an additional 393 shares during the period. Finally, EverSource Wealth Advisors LLC boosted its holdings in shares of Henry Schein by 167.4% during the 1st quarter. EverSource Wealth Advisors LLC now owns 936 shares of the company’s stock valued at $69,000 after acquiring an additional 586 shares during the last quarter. Institutional investors own 96.62% of the company’s stock.

Key Headlines Impacting Henry Schein

Here are the key news stories impacting Henry Schein this week:

• Positive Sentiment: Zacks upgraded Henry Schein to Rank #2 (Buy), citing improving earnings prospects—a potentially supportive signal for the shares. Read More.
• Positive Sentiment: Bank of America Securities maintained its Buy rating, reinforcing a favorable analyst view. Read More.
• Positive Sentiment: UBS raised its price target to $95 from $94. It kept a Neutral rating, so the higher target is constructive but not a change to its overall recommendation. Read More.
• Positive Sentiment: In its latest reported quarter, Henry Schein posted EPS of $1.56, beating the $1.36 consensus estimate; revenue grew 4% year over year. Read More.
• Neutral Sentiment: Revenue of $3.47 billion was slightly below the $3.48 billion estimate, tempering the earnings beat. Read More.
• Neutral Sentiment: The company plans to participate in investor conferences in November and December; no new financial outlook was reported in the announcement. Read More.

Henry Schein Company Profile

Henry Schein, Inc (NASDAQ: HSIC) is a global provider of healthcare products and services serving dental and medical professionals, as well as veterinary practices and laboratories. The company distributes consumable supplies, equipment, pharmaceuticals, vaccines, and other products used in clinical and practice-management settings.

In addition to product distribution, Henry Schein provides technology solutions and value-added services designed to support clinical workflows, electronic health records, practice management, procurement, equipment installation, and technical support.